Shanghai Junshi Biosciences
Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical company based in Shanghai, China, focused on the discovery, development, and commercialization of drugs primarily in the fields of oncology, metabolic disorders, autoimmunity, and neurology. The company offers TUOYIR, a recombinant humanized anti-PD-1 monoclonal antibody for various cancers, including melanoma and non-small cell lung carcinoma. Additionally, it is developing several other therapeutics, such as UBP1211, a biosimilar of Humira for rheumatoid arthritis, and JS002, an anti-PCSK9 monoclonal antibody for hyperlipidemia, among others. Junshi Biosciences is actively engaged in clinical trials for its products, with several candidates in Phase I and II stages. The company has established collaborations with major pharmaceutical firms, including Eli Lilly and Merck, to advance research on therapeutic antibodies and immunotherapies. Founded in 2012, Shanghai Junshi Biosciences aims to contribute to the global biopharmaceutical landscape through innovative solutions and strategic partnerships.
GRIT Biotechnology is engaged in research and development of tumor infiltration lymphocytes immunotherapy for curing solid tumors. The company is based in Shanghai, China.
Zhishan Weixin Biotechnology
Series A in 2021
Zhishan Weixin Biotechnology integrates gene-drug research and development to treat genetic and neurodegenerative diseases. The company focuses on the research and development and subversive production of rAAV gene drugs. Zhishan Weixin's therapeutic areas cover blood diseases, rare diseases, and other disease areas.
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company based in Redwood City, California, that specializes in the development, manufacture, and marketing of biosimilar therapeutics. It primarily targets the oncology and inflammatory disease markets with its product offerings. The company's flagship product, UDENYCA, is a biosimilar to Neulasta, designed to stimulate the production of granulocytes to enhance the body’s infection-fighting capabilities. Coherus is also advancing several other biosimilar candidates, including those for Humira and Enbrel, which have completed Phase III clinical studies. Additionally, the company is working on biosimilars for other biologics, including ranibizumab and aflibercept, as well as a small-molecule drug for metabolic conditions. Coherus BioSciences was founded in 2010 and has established various license agreements to support its product development initiatives.
IMPACT Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and commercializing therapeutics for cancer and other serious diseases. Founded in 2009 and headquartered in Shanghai, China, the company is engaged in several research and development projects, including the development of PARP inhibitors, Wee1 inhibitors, novel DNA damage response agents, and Hedgehog pathway inhibitors. IMPACT Therapeutics aims to create best-in-class drugs with independent intellectual property rights, emphasizing the discovery of targeted anti-cancer therapies based on the principle of synthetic lethality. The company’s management team possesses extensive experience in drug development and management, with a strong background in pharmacology and biology, which supports its mission to provide innovative treatments for patients with life-threatening conditions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.